116 research outputs found
New world, other value
No full textRecent studies on artistic modernism pay particular attention to the art histories of the non-West by doing less with Western theoretical conducts and how they define “modern art.” The present book, in line with these studies, surveys artistic modernism while it recognizes “modernism” as a response to confluences of social, economic and political forces. The book thus skips frameworks of a comparative study for the strategies that mainly aim to unveil similarities or dissimilarities between what is modern and what is not. It instead returns to and captures the ways artists conceived their works as modern art; moreover, it collects documents which better display the relation between these works and their contextual causes: What is needed more now is an understanding of the necessities which encouraged artists into creating new forms as absolute responses.
Parastoo Jafari completed her master’s degree in art research at IAU Tehran with an interest in artistic developments of post–Islamic Revolution Iran. She received a doctoral degree in art history at LMU Munich focusing on material and intellectual contexts of artistic modernism. She collaborated as research assistant with Walter De Gruyter and University of Munich, contributed to curatorial projects on Iranian art and, as an author and translator, works with topics relating to modern and contemporary art with particular attention to Iran
Discrepancy of Graham Greene
No full textLack of religious sense in twentieth century made so many writers to object to the situation. One of these writers who had devoted a very challenging criticism to himself is Graham Greene. In criticizing Greene’s novels there has always been an argument that Is there any relationship between his novels and his personal life? In this article the role of Catholicism Graham Greene’s works and his own personal life has been examined. In order observe such a role we need a very detailed examination of Greene’s life, his personal letters, his conversations and his works. According to so many critics the close relationship between Greene’s life and his works is not ignorable. So by applying Biographical Criticism on Graham Greene it is obvious that about this writer the death of author does not work. The prominent figure of the writer seems to be present in each story and each action.
H-index and research evaluation: A suggested set of components for developing a comprehensive author-level index
No full textThe H-index has been investigated in various studies; this index has many strengths that have made it popular. However, it also has weaknesses, due to which other indicators have been developed. This study aims to identify the strengths and weaknesses of the H-index and provide the minimum set of necessary components for developing a comprehensive author-level index. In this systematic literature review, Scopus, PubMed, Web of Science, Emerald, and ProQuest databases were searched to identify relevant studies. From the number of 14,253 retrieved studies, after two stages of screening, 81 studies were selected according to the eligibility criteria for data extraction. The findings of the study led to the identification of 15 strengths in the three categories of Quality Features, Simplicity, and Suitability, and 13 weaknesses in the six categories of Publications, Citations, Academic Age, Author Credit Allocation, Variety of Fields, and mathematical calculation for H-index. Finally, 28 components were identified as the minimum set of necessary components to develop a comprehensive author-level index to help evaluate researchers more realistically and fairly. The minimum components that need to be considered in developing a comprehensive author-level index can be proposed as follows: Quality Features, Simplicity, Suitability, Publications, Citations, Academic Age, Author Credit Allocation, Variety of Fields, and mathematical calculation
Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma
No full textRecommended from our members
Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma
No full textIntroduction: Majority of patients with Hodgkin lymphoma (HL) can be successfully cured with frontline conventional therapeutics. Approximately 50-60% of those whose disease recur or is refractory to conventional treatment, can be cured with salvage therapies followed by autologous hematopoietic cell transplantation (AHCT). Conventional treatments, however, may cause significant long-term toxicities.
Areas covered: This article reviews the treatment advances in HL with the incorporation of novel and targeted agents that are aimed to improve cure rates while reducing toxicities.
Expert opinion: Brentuximab vedotin (BV) and checkpoint inhibitors have demonstrated clear clinical benefit in HL. Majority of patients receive BV before or directly after AHCT as part of salvage or maintenance regimens. In patients who relapse after AHCT, checkpoint inhibitors are the treatment of choice, either as a stand-alone therapy or more commonly as a bridge to a potentially curative allogeneic hematopoietic cell transplantation (alloHCT). A multitude of other targeted agents and combinations, as well as cellular and immunotherapeutic in HL, are under investigation
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma
No full text
Recommended from our members
Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma
No full textIntroduction: Molecular and biologic heterogeneity in diffuse large B-cell lymphoma (DLBCL) has resulted in a broad range of clinical outcomes. While standard frontline chemoimmunotherapy cures majority of patients with DLBCL, treatment failure in certain DLBCL subsets remains high. Prognosis in these patients is dismal. Therefore, optimization of front-line therapy, as well as development of more effective salvage treatments, is an unmet medical need.
Areas covered: This article reviews the treatment advances in DLBCL with novel and targeted agents that are aimed to improve efficacy especially in those with high-risk features.
Expert opinion: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in the treatment of higher-risk DLBCL subgroups have shown to be effective; however, confirmatory data are required to change the standard of care. While autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19-positive B-cells have revolutionized the outcomes of refractory DLBCL, the complexity of its production, post-infusion care, and the associated cost, currently has limited its use to select academic centers in the US. A multitude of other targeted agents and combinations as well as cellular and immunotherapeutic agents are under investigation
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis
No full text- …
